Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1264146
                    [Title] => Drug tackles new challenges in kidney, liver transplants
                    [Summary] => 
A paradigm shift in kidney transplantation in the last decade has shifted the focus from preventing acute organ rejection to preventing chronic graft (transplanted kidney) dysfunction and mortality in transplant patients with functioning grafts.

                    [DatePublished] => 2013-12-05 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 862112
                    [Title] => Novartis drug offers new tack in cancer treatment
                    [Summary] => 
Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

                    [DatePublished] => 2012-11-01 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 473898
                    [Title] => Once-daily tablet for advanced kidney cancer approved in US
                    [Summary] => 
MANILA,  Philippines – Patients with metastatic renal cell carcinoma (mRCC) or advanced kidney cancer will soon benefit from a breakthrough therapy for this difficult-to-treat disease.
                    [DatePublished] => 2009-06-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

EVEROLIMUS

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 1264146
                    [Title] => Drug tackles new challenges in kidney, liver transplants
                    [Summary] => 
A paradigm shift in kidney transplantation in the last decade has shifted the focus from preventing acute organ rejection to preventing chronic graft (transplanted kidney) dysfunction and mortality in transplant patients with functioning grafts.

                    [DatePublished] => 2013-12-05 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 862112
                    [Title] => Novartis drug offers new tack in cancer treatment
                    [Summary] => 
Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

                    [DatePublished] => 2012-11-01 00:00:00
                    [ColumnID] => 0
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => http://imageshack.us/a/img27/6591/scitec4newthumb.jpg
                )

            [2] => Array
                (
                    [ArticleID] => 833899
                    [Title] => Novartis cancer drug gets Phl FDA approval
                    [Summary] => 
The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer, in postmenopausal women after recurrence or progression following endocrine therapy.
                    [DatePublished] => 2012-08-02 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 473898
                    [Title] => Once-daily tablet for advanced kidney cancer approved in US
                    [Summary] => 
MANILA,  Philippines – Patients with metastatic renal cell carcinoma (mRCC) or advanced kidney cancer will soon benefit from a breakthrough therapy for this difficult-to-treat disease.
                    [DatePublished] => 2009-06-04 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Drug tackles new challenges in kidney, liver transplants

December 5, 2013 - 12:00am

A paradigm shift in kidney transplantation in the last decade has shifted the focus from preventing acute organ rejection to preventing chronic graft (transplanted kidney) dysfunction and mortality in transplant...

Science and Environment

Novartis drug offers new tack in cancer treatment

November 1, 2012 - 12:00am

Endocrine therapy remains the cornerstone of treatment for postmenopausal women with hormone receptor-positive (HR+), HER2/neu-negative...

Science and Environment

Novartis cancer drug gets Phl FDA approval

August 2, 2012 - 12:00am

The Novartis anti-cancer drug everolimus, in combination with aromatase inhibitor, is now approved in the Philippines for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast...

Science and Environment

Once-daily tablet for advanced kidney cancer approved in US

June 4, 2009 - 12:00am

MANILA, Philippines – Patients with metastatic renal cell carcinoma (mRCC) or advanced kidney cancer will soon benefit from a breakthrough therapy for this difficult-to-treat disease.

Science and Environment